Tiny electronic sensors and devices that can be implanted in the body and then dissolve almost without a trace are getting closer to reality. Scientists have tested several biodegradable materials, including DNA, proteins and metals, for making transient electronics.
FUJIFILM VisualSonics Inc., a world leader in ultra high frequency ultrasound imaging systems and subsidiary of FUJIFILM SonoSite, Inc., today announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Vevo® MD, the world’s first Ultra High Frequency (UHF) clinical ultrasound system. With multiple successes in preclinical research over the last decade, the Vevo® MD is FUJIFILM VisualSonics’ first foray into the clinical market.
The Gatorade Company, Inc., a manufacturer of sports-themed beverage and food products, recently announced the launch of Bolt Breakers, an innovation project in collaboration with CoreSyte, Facebook, Spotify and Twitter to develop new technology platforms that will ultimately help athletes fuel their game.
Profusa, Inc., a leading developer of tissue-integrated biosensors, today announced that the National Institutes of Health has awarded it a $1.75 million grant under the Small Business Innovation Research (SBIR) program. Administered by the National Heart, Lung, and Blood Institute (NHLBI), the funding will support Fast-tracked Phase I and Phase II studies of the company's Lumee™ tissue-integrated biosensors for continuous monitoring of oxygen toward improving the clinical outcomes of patients suffering from peripheral artery disease (PAD).
For epilepsy patients and attending physicians, it has been a challenge to correctly assess the frequency and severity of epileptic seizures without inpatient recording equipment. A consortium coordinated by the epileptologists of the University Hospital Bonn is now developing a mobile sensor that can detect seizures. A warning signal is designed to summon relatives or attending physicians to provide timely help.
Rice University synthetic biologist Jeffrey Tabor is intent upon making the gut check standard operating procedure.
Mitochondrial dysfunction plays a critical role in the development of chemical and pharmaceutical toxicity. However, current methods to evaluate mitochondrial activity still rely on traditional tests called end-point assays, which provide limited prognostic information.
Diagnosing disease can be highly technical, costly and time-consuming, which are all challenges that become particularly problematic in low-income and remote locations. Now scientists are reporting in the journal ACS Applied Materials & Interfaces a new way to repurpose portable glucose monitors to harness these simple devices' practicality and low cost for the detection of other diseases.
Xbox Kinects could be used in the future to assess the health of patients with conditions such as cystic fibrosis.
Varian Medical Systems today announced a new Calypso® 17G soft tissue Beacon® transponder that is 50 percent smaller than the previous version. The 17G device can help enhance the precision of radiotherapy and radiosurgery treatments for cancer by providing real-time, continuous tumor position information, based on the implanted transponders, and has received FDA 510(k) clearance and CE mark.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.